Our results demonstrated that combining cilengitide with anti-PD1 monoclonal antibody enhanced CD8+ TILs infiltration in tumor and spleen tissues, thereby inhibiting local tumor growth and prolonging the survival period. The gene discussed is PDCD1; the disease is neoplasm.